NCT05406362View on ClinicalTrials.gov

Assess Safety and Efficacy of VAD044 in HHT Patients

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

July 18, 2022

Primary Completion Date

March 31, 2025

Study Completion Date

December 31, 2025

Conditions
Hereditary Hemorrhagic Telangiectasia (HHT)
Interventions
DRUG

VAD044 Part I

capsules to be taken once daily for 12 weeks

DRUG

VAD044 Part II

capsules to be taken once daily for 12 months

Trial Locations (7)

02114

Massachusetts General Hospital, Boston

Unknown

Universitair Ziekenhuis Gent, Ghent

Hospices Civils de Lyon, Lyon

Ospedale Maggiore di Crema, Crema

St. Antonius Hospital, Nieuwegein

Hospital Universiati De Bellvitge, Barcelona

Hospital Universitario Ramón y Cajal, Madrid

All Listed Sponsors
lead

Vaderis Therapeutics AG

INDUSTRY